Xeris Biopharma CEO Paul Edick joined Proactive's Natalie Stoberman to share the resignation of the company's Chief Scientific Officer and Founder Dr. Steven Prestrelski as he transitions to a consulting role with Xeris.
Edick said the impact of Dr. Prestrelski stepping down as the CSO will be negligible as Xeris Biopharma has transitioned from a research and development company to primarily a commercial business with development activities. Edick adds that Xeris Biopharma will retain Dr. Prestrelski as a consultant for the next year or two as needed.
Edick also expressed excitement for Dr. Prestrelski's future endeavours, potentially starting another company focused on peptides and research which aligns more with his interests, and emphasized that the rest of the company is operating well with a healthy business, three growing products, partnerships with Big Pharma, and another product in the pipeline.
View source version on newsdirect.com: https://newsdirect.com/news/xeris-biopharma-ceo-reveals-impact-of-csos-departure-and-exciting-future-plans-935470532
Xeris Biopharma Holdings